Developing a Gram-Negative Selective Peptide-Drug Conjugate

Area of Science:

• Microbiology
• Drug Discovery
• Molecular Biology

Background:

• Antibiotic resistance, particularly to fluoroquinolones like ciprofloxacin, poses a significant global health threat.
• Proline-rich antimicrobial peptides (PrAMPs) like oncocin show promise but require enhanced potency.
• Developing multi-modal antibiotics is crucial for overcoming resistance mechanisms.

Purpose of the Study:

• To create and evaluate a novel conjugate combining ciprofloxacin and oncocin.
• To assess the enhanced potency and spectrum of activity of the conjugate against bacterial strains.
• To investigate the molecular interactions and mechanisms of action of the conjugate.

Main Methods:

• Conjugation of ciprofloxacin to the oncocin peptide.
• Determination of Minimum Inhibitory Concentration (MIC) to assess potency.
• Characterization of interactions with intracellular targets (DnaK, 70S ribosome, gyrase).
• Evaluation of mast cell degranulation capacity.

Main Results:

• The conjugate (oncocin-cipro-c) demonstrated approximately threefold increased potency compared to oncocin alone.
• The conjugate maintained selectivity for Gram-negative bacteria.
• Oncocin-cipro-c effectively targeted multiple intracellular bacterial components, including DnaK, 70S ribosome, and gyrase.
• The conjugate induced mast cell degranulation at lower concentrations than the parent peptide.

Conclusions:

• The oncocin-cipro-c conjugate represents a promising multi-modal antibiotic candidate.
• This strategy enhances antimicrobial potency and broadens the mechanism of action.
• Development of such conjugates is vital for addressing the escalating challenge of antibiotic resistance.